Compare Enveric Biosciences Inc (ENVB) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs New York Times Co — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while New York Times Co trades at $63.74 (market cap $10.45B). The key difference: New York Times Co is far larger — about 1685.5× Enveric Biosciences Inc's market cap, and New York Times Co pays a 1.42% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NYT | |
|---|---|---|
Market Cap | $6.20M | $10.45B |
Sector | Health | Media |
52-Week High | $17.40 | $85.86 |
52-Week Low | $1.27 | $54.66 |
Enterprise Value | $1.30M | $9.85B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
The New York Times (NYT) stock trades at $63.54, down 1.9% recently, with a bearish technical signal from moving averages but neutral oscillators. Fundamentally, the company shows strong profitability with a 13.19% net income margin and consistent earnings beats, including Q2 2026 EPS of $0.69 versus $0.663 expected. Revenue growth is steady, reaching $2.82B in 2025, though digital subscriber additions have moderated, contributing to near-term stock weakness.
Outlook remains mixed; analyst consensus targets $77.50 with 29% buy ratings, but slower subscriber growth and high valuation (P/E 26.48) pose risks. Opportunities include digital expansion and pricing power, while risks involve competition and economic sensitivity. The stock's current level near support at $63 may attract value-oriented investors if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
